ENDPOINTS

Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia

Eli Lilly’s RNA candidate has reduced levels of a protein linked with cardiovascular disease risk in a mid-stage trial in patients with high cholesterol. Solbinsiran, a small interfering RNA, administered at a 400 mg dose ...

Apr 1, 2025 - 11:53
 0
Lilly claims Phase 2 win for siRNA approach to mixed dyslipidemia
Eli Lilly’s RNA candidate has reduced levels of a protein linked with cardiovascular disease risk in a mid-stage trial in patients with high cholesterol. Solbinsiran, a small interfering RNA, administered at a 400 mg dose ...
Read More

Tags:

Previous Article

How to get rid of toxic ‘forever chemical’ pollution

Next Article

Meet the electric scooter that’ll make your car jealous—and it’s $79 off

Related Posts

BioNTech details promising mid-stage data for its PD-L1xVEGF in aggressive lung cancer

BioNTech details promising mid-stage data for its PD-L1...

Mar 28, 2025  0

UnitedHealth's Optum Rx to change its payment models

UnitedHealth's Optum Rx to change its payment models

Mar 20, 2025  0

Why did radiopharma biotech Actinium hold an investor event at Mar-a-Lago?

Why did radiopharma biotech Actinium hold an investor e...

Mar 26, 2025  0